{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.6","upperLimit":"27.7","value":"20"},{"groupId":"OG001","lowerLimit":"6.5","upperLimit":"18.0","value":"11.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"Improvement of Response (IOR) is the percentage of participants with improved tumor response during the maintenance phase (converted from partial response at end of induction to complete response or complete response unconfirmed as best response) and participants who converted from stable disease at the end of induction period to partial response or better as best response during maintenance phase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"NUMBER","populationDescription":"All randomized participants in Arm A and Arm B, as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From the first dose date of maintenance therapy to death from any cause (up to approximately 432 weeks)","title":"Improvement of Response (IOR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}